172 related articles for article (PubMed ID: 24510534)
1. Optimization of individualized dynamic treatment regimes for recurrent diseases.
Huang X; Ning J; Wahed AS
Stat Med; 2014 Jun; 33(14):2363-78. PubMed ID: 24510534
[TBL] [Abstract][Full Text] [Related]
2. Optimization of multi-stage dynamic treatment regimes utilizing accumulated data.
Huang X; Choi S; Wang L; Thall PF
Stat Med; 2015 Nov; 34(26):3424-43. PubMed ID: 26095711
[TBL] [Abstract][Full Text] [Related]
3. Estimating individualized treatment rules in longitudinal studies with covariate-driven observation times.
Coulombe J; Moodie EE; Shortreed SM; Renoux C
Stat Methods Med Res; 2023 May; 32(5):868-884. PubMed ID: 36927216
[TBL] [Abstract][Full Text] [Related]
4. Analysis of multi-stage treatments for recurrent diseases.
Huang X; Ning J
Stat Med; 2012 Oct; 31(24):2805-21. PubMed ID: 22826139
[TBL] [Abstract][Full Text] [Related]
5. Adaptive contrast weighted learning for multi-stage multi-treatment decision-making.
Tao Y; Wang L
Biometrics; 2017 Mar; 73(1):145-155. PubMed ID: 27213913
[TBL] [Abstract][Full Text] [Related]
6. Evaluating Joint Effects of Induction-Salvage Treatment Regimes on Overall Survival in Acute Leukemia.
Wahed AS; Thall PF
J R Stat Soc Ser C Appl Stat; 2013 Jan; 62(1):67-83. PubMed ID: 24014891
[TBL] [Abstract][Full Text] [Related]
7. Optimal two-stage dynamic treatment regimes from a classification perspective with censored survival data.
Hager R; Tsiatis AA; Davidian M
Biometrics; 2018 Dec; 74(4):1180-1192. PubMed ID: 29775203
[TBL] [Abstract][Full Text] [Related]
8. HIGH-DIMENSIONAL A-LEARNING FOR OPTIMAL DYNAMIC TREATMENT REGIMES.
Shi C; Fan A; Song R; Lu W
Ann Stat; 2018 Jun; 46(3):925-957. PubMed ID: 29805186
[TBL] [Abstract][Full Text] [Related]
9. Dynamic Treatment Regimes Using Bayesian Additive Regression Trees for Censored Outcomes.
Li X; Logan BR; Hossain SMF; Moodie EEM
Lifetime Data Anal; 2024 Jan; 30(1):181-212. PubMed ID: 37659991
[TBL] [Abstract][Full Text] [Related]
10. Application of multi-state models in cancer clinical trials.
Le-Rademacher JG; Peterson RA; Therneau TM; Sanford BL; Stone RM; Mandrekar SJ
Clin Trials; 2018 Oct; 15(5):489-498. PubMed ID: 30035644
[TBL] [Abstract][Full Text] [Related]
11. Treatment-competing events in dynamic regimes.
Johnson BA
Lifetime Data Anal; 2008 Jun; 14(2):196-215. PubMed ID: 17828622
[TBL] [Abstract][Full Text] [Related]
12. Optimal dynamic regimes: presenting a case for predictive inference.
Arjas E; Saarela O
Int J Biostat; 2010 Mar; 6(2):Article 10. PubMed ID: 20648215
[TBL] [Abstract][Full Text] [Related]
13. Dynamic regime marginal structural mean models for estimation of optimal dynamic treatment regimes, Part I: main content.
Orellana L; Rotnitzky A; Robins JM
Int J Biostat; 2010; 6(2):Article 8. PubMed ID: 21969994
[TBL] [Abstract][Full Text] [Related]
14. C-learning: A new classification framework to estimate optimal dynamic treatment regimes.
Zhang B; Zhang M
Biometrics; 2018 Sep; 74(3):891-899. PubMed ID: 29228509
[TBL] [Abstract][Full Text] [Related]
15. Response in acute myeloid leukemia.
Estey E
Clin Adv Hematol Oncol; 2008 Feb; 6(2):113-7. PubMed ID: 18347562
[TBL] [Abstract][Full Text] [Related]
16. On optimal treatment regimes selection for mean survival time.
Geng Y; Zhang HH; Lu W
Stat Med; 2015 Mar; 34(7):1169-84. PubMed ID: 25515005
[TBL] [Abstract][Full Text] [Related]
17. International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia.
Roboz GJ; Rosenblat T; Arellano M; Gobbi M; Altman JK; Montesinos P; O'Connell C; Solomon SR; Pigneux A; Vey N; Hills R; Jacobsen TF; Gianella-Borradori A; Foss Ø; Vetrhusand S; Giles FJ
J Clin Oncol; 2014 Jun; 32(18):1919-26. PubMed ID: 24841975
[TBL] [Abstract][Full Text] [Related]
18. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.
Pemovska T; Kontro M; Yadav B; Edgren H; Eldfors S; Szwajda A; Almusa H; Bespalov MM; Ellonen P; Elonen E; Gjertsen BT; Karjalainen R; Kulesskiy E; Lagström S; Lehto A; Lepistö M; Lundán T; Majumder MM; Marti JM; Mattila P; Murumägi A; Mustjoki S; Palva A; Parsons A; Pirttinen T; Rämet ME; Suvela M; Turunen L; Västrik I; Wolf M; Knowles J; Aittokallio T; Heckman CA; Porkka K; Kallioniemi O; Wennerberg K
Cancer Discov; 2013 Dec; 3(12):1416-29. PubMed ID: 24056683
[TBL] [Abstract][Full Text] [Related]
19. Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission.
Buyse M; Michiels S; Squifflet P; Lucchesi KJ; Hellstrand K; Brune ML; Castaigne S; Rowe JM
Haematologica; 2011 Aug; 96(8):1106-12. PubMed ID: 21546500
[TBL] [Abstract][Full Text] [Related]
20. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
